Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor…
16 analysts rate SYRE Buy on consensus.
Consensus price target: $122.33 (+35.43% upside from $90.33)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Burrows Scott L Chief Financial Officer | Oct 1, 2026 | Sale | 1,500 | $135.41K |
| Turtle Cameron director, Chief Executive Officer | Oct 1, 2026 | Sale | 4,990 | $465.92K |
| Burrows Scott L Chief Financial Officer | Oct 1, 2026 | Sale | 229 | $21.43K |
| Burrows Scott L Chief Financial Officer | Oct 1, 2026 | Sale | 2,100 | $193.03K |
| Turtle Cameron director, Chief Executive Officer | Oct 1, 2026 | Sale | 2,638 | $241.35K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-155.2M |
| 2024 | $0 | -100% | $-208.02M |
| 2023 | $886K | -61.96% | $-338.79M |
Stock data for SYRE: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics